- ¥490 - 1190
- Solarbio
- II3920
- 北京
- 2026年08月14日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
细胞污染识别与处理全攻略：5 种常见类型+关键误区Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 库存：
999
- 英文名：
Infigratinib Phosphate
- CAS号：
1310746-10-1
- 保质期：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 供应商：
北京索莱宝科技有限公司
- 保存条件：
Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year
- 规格：
5mg/10mg/50mg
| 规格： | 5mg | 产品价格： | ¥490.00 |
|---|---|---|---|
| 规格： | 10mg | 产品价格： | ¥590.00 |
| 规格： | 50mg | 产品价格： | ¥1190.00 |
| CAS | 1310746-10-1 |
| 英文名称 | Infigratinib Phosphate |
| 分子式 | C26H34Cl2N7O7P |
| 分子量 | 658.47 |
| 规格 | 5mg ; 10mg ; 50mg |
| 溶解性 | Soluble in DMSO ≥1mg/mL |
| 纯度 | ≥98% |
| 外观(性状) | Off-white to gray Solid |
| 储存条件 | Powder:2-8℃，2 years;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 | 冷藏运输 |
| SMILES | CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl.OP(=O)(O)O |
| InChIKey | GUQNHCGYHLSITB-UHFFFAOYSA-N |
| InChI | InChI=1S/C26H31Cl2N7O3.H3O4P/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28;1-5(2，3)4/h6-9，14-16H，5，10-13H2，1-4H3，(H，32，36)(H，29，30，31);(H3，1，2，3，4) |
| PubChem CID | 56669626 |
| 靶点 | FGFR |
| 通路 | Angiogenesis; Protein Tyrosine Kinase/RTK |
| 背景说明 | Infigratinib phosphate是 FGFR 抑制剂。 |
| 生物活性 | Infigratinib phosphate (BGJ-398 phosphate; NVP-BGJ398 phosphate) is a potent inhibitor of the FGFR family with IC50 of 0.9 nM， 1.4 nM， 1 nM， and 60 nM for FGFR1， FGFR2， FGFR3， and FGFR4， respectively.[1-2] |
| In Vitro | Infigratinib phosphate inhibits FGFR1， FGFR2， and FGFR3 with IC50=~1 nM， FGFR3K650E with IC50=4.9 nM， and FGFR4 with IC50=60 nM. IC50 values for all other kinases are in the μM range (FYN， LCK， YES， and ABL， IC50=1.9， 2.5， 1.1， and 2.3 μM， respectively) except for VEGFR2， KIT， and LYN， which are inhibited at submicromolar concentrations (IC50=0.18， 0.75， and 0.3 μM， respectively). Infigratinib inhibits the proliferation of the FGFR1-， FGFR2-， and FGFR3-dependent BaF3 cells with IC50 values which are in the low nanomolar range and comparable to those observed for the inhibition of the receptors kinase activity in the enzymatic assay. For the remaining cells， all IC50 values are greater than 1.5 μM except for VEGFR2 (IC50 1449 and 938 nM)， for which there is at least a 400-fold selectivity versus FGFR1， FGFR2， and FGFR3[1]. Infigratinib (ranging between 1 nM and 10 μM) is potent at inhibiting cell growth of FGFR2-mutant endometrial cancer cells[2]. |
| In Vivo | Infigratinib is administered to athymic nude mice implanted subcutaneously with RT112/luc1 tumors: either as a 5 mg/kg intravenous bolus in NMP/PEG200 (1:9， v/v) or orally by gavage as a suspension in PEG300/D5W (2:1， v/v) at a 20 mg/kg dose. The relevant pharmacokinetic (PK) parameters indicate that the oral bioavailability of Infigratinib in this study is 32%. After intravenous dosing， Infigratinib shows a rapid distribution from the vascular compartment into the peripheral tissues， translating into a high volume of distribution (26 L/kg). The plasma clearance is high at 3.3 L/h/kg (61% of liver blood flow). The ratio of tumor to plasma after oral dosing based on AUC is determined to be 10[1]. Infigratinib (30 mg/kg) significantly inhibits the growth of FGFR2-mutated endometrial cancer xenograft models[2]. |
| 细胞实验 | Murine BaF3 cell lines are cultured in RPMI-1640 media supplemented with 10% FBS， 4.5 g/L glucose， 1.5 g/L sodium bicarbonate， and Pen/Strep. Cells are passaged twice weekly. Compound-mediated inhibition of BaF3 cell proliferation and viability is assessed using a Luciferase bioluminescent assay. Exponentially growing BaF3 or BaF3 Tel-TK cells are seeded into 384-well plates (4250 cells/well) at 50 μL/well using a μFill liquid dispenser in fresh medium. Infigratinib is serially diluted in DMSO and arrayed in a polypropylene 384-well plate. Then 50 nL of compound are transferred into the plates containing the cells by using the pintool transfer device， and the plates incubated at 37°C (5% CO2) for 48 h. Then 25 μL of Bright-Glo are added， and luminescence is quantified using an Analyst-GT. Custom curve-fitting software is used to produce a logistic fit of percent cell viability as a function of the logarithm of inhibitor concentration. The IC50 value is determined as the concentration of compound needed to reduce cell viability to 50% of a DMSO control[1]. |
| 动物实验 | Mice[1] Female HsdNpa: Athymic Nude-nu mice are used. Infigratinib is formulated as a suspension in PEG300/D5W (2:1， v/v) and administered orally for 12 consecutive days at the doses of 10 and 30 mg/kg/qd. Tumor and body weight data are analyzed by ANOVA with post hoc Dunnett’s test for comparison of treatment versus control group. The post hoc Tukey test is used for intragroup comparison. Statistical analysis is performed using GraphPad prism 4.02. As a measure of efficacy， the T/C (%) value is calculated. Rats[1] Female nude Rowett rats 6-9 weeks of age are used. Infigratinib is formulated as a solution in acetic acid-acetate buffer pH 4.6/PEG300 (1:1， v/v) and applied daily by gavage to the tumor-bearing rats (n=8) for 20 consecutive days at doses of 5， 10， and 15 mg/kg/qd (free base equivalents). The application volume is 5 mL/kg. Tumor volumes are measured with calipers and determined according to the formula: length×width×height×π/6. Antitumor activity is expressed as T/C (%): (mean change of tumor volume of treated animals/mean change of tumor volume of control animals)×100. Regressions (%) are calculated. |
| 激酶实验 | The enzymatic kinase activity is assessed by measuring the phosphorylation of a synthetic substrate by the purified GST-fusion FGFR3-K650E kinase domain， in the presence of radiolabeled ATP. Enzyme activities are measured by mixing 10 μL of a 3-fold concentrated Infigratinib solution or control with 10 μL of the corresponding substrate mixture (peptidic substrate， ATP and [γ33P]ATP). The reactions are initiated by addition of 10 μL of a 3-fold concentrated solution of the enzyme in assay buffer. The final concentrations of the assay components are as following: 10 ng of GST-FGFR3-K650E， 20 mM Tris-HCl， pH 7.5， 3 mM MnCl2， 3 mM MgCl2， 1 mM DTT， 250 μg/mL PEG 20000， 2 μg/mL poly(EY) 4:1， 1% DMSO and 0.5 μM ATP (γ-[33P]-ATP 0.1 μCi). The assay is carried out according to the filter binding (FB) method in 96-well plates at room temperature for 10 min in a final volume of 30 μL including the components as indicated above. The enzymatic reactions are stopped by the addition of 20 μL of 125 mM EDTA， and the incorporation of 33P into the polypeptidic substrates is quantified as following: 30 μL of the stopped reaction mixture are transferred onto Immobilon-PVDF membranes previously soaked for 5 min with methanol， rinsed with water， soaked for 5 min with 0.5% H3PO4， and mounted on vacuum manifold with disconnected vacuum source. After spotting， vacuum is connected， and each well rinsed with 0.5% H3PO4 (200 μL). Free membranes are removed and washed four times on a shaker with 1% H3PO4 and once with ethanol. Membranes are dried and overlaid with addition of 10 μL/well of a scintillation fluid. The plates are eventually sealed and counted in a microplate scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition of NVP-BGJ398[1]. |
| 数据来源文献 | [1]. Guagnano V， et al. Discovery of 3-(2，6-Dichloro-3，5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-me thyl-urea (NVP-BGJ398)， A Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor T [2]. Konecny GE， et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42. |
| 单位 | 瓶 |
| 表格1 | |*|1mg|5mg|10mg|$$|1mM|1.5187mL|7.5934mL|15.1867mL|$$|5mM|0.3037mL|1.5187mL|3.0373mL|$$|10mM|0.1519mL|0.7593mL|1.5187mL| |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
亦称为三碳糖磷酸，是 3-磷酸甘油醛和二羟丙酮（ dihydroxyacetone）磷酸的平衡混合物。 磷酸丙糖异构酶参与此平衡反应。在糖酵解的过程中，由 1， 6- 二磷酸果糖经醛缩酶（ aldolase）的作用解裂生成，通过 3- 磷酸甘油醛 - 脱氢酶（ dehyd－ rogenase）能可逆的被磷酸化和氧化而产生 1， 3－二磷酸甘油酸。也可以作为光合成过程（还原型戊糖磷酸循环）的中间产物而生成。
磷酸原之一。是 P． Eggle－ ton和 G． P． Eggleton（ 1927） 首先从猫的肌肉中发现的，它广泛地存在于脊椎动物的肌肉中。为无色水溶性，其钠盐、钙盐也可溶于水。具有高能磷酸键（Δ G°′ = - 10.3千卡）在酸性溶液中，易分解成肌酸与正磷酸，在中性溶液中，比较稳定。在生物体内由肌酸和 ATP经酶的作用合成，但反应是可逆的，呈如下的平衡（称为肌酸激酶反应，过去称为 Lohmann反应）：
1. Make standards using sodium phosphate at the following uM concentrations: 0, 2, 5, 7, 10, 20, 40, 60, and 80. Use the screw top glass tubes. 2. Dry the samples and standards under nitrogen evaporator (Rm 209), and add 150 ul 70
技术资料需要更多技术资料 索取更多技术资料
Infigratinib phosphate
¥490 - 1190
